Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cowealth Medical Holding Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:4745'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.7 Med: 2.14 Max: 5.17
Current: -5.7
During the past 13 years, the highest Debt-to-EBITDA Ratio of Cowealth Medical Holding Co was 5.17. The lowest was -5.70. And the median was 2.14.
ROCO:4745's Debt-to-EBITDA is ranked worse than 100% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs ROCO:4745: -5.70
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cowealth Medical Holding Co Debt-to-EBITDA Related Terms
Cowealth Medical Holding Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4745 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Cowealth Medical Holding Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cowealth Medical Holding Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cowealth Medical Holding Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cowealth Medical Holding Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Cowealth Medical Holding Co (ROCO:4745) has a Debt-to-EBITDA of -7.67 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cowealth Medical Holding Co. According to the industry distribution chart, Cowealth Medical Holding Co ranks #999999 out of 475 companies in the Medical Devices & Instruments industry.
Is Cowealth Medical Holding Co's Debt-to-EBITDA too high?
Cowealth Medical Holding Co's current Debt-to-EBITDA is -7.67. Based on the distribution chart, Cowealth Medical Holding Co ranks #999999 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cowealth Medical Holding Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cowealth Medical Holding Co's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cowealth Medical Holding Co ranks #999999 out of 475 companies for Debt-to-EBITDA. This places Cowealth Medical Holding Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.61, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cowealth Medical Holding Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cowealth Medical Holding Co's current Debt-to-EBITDA is -7.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cowealth Medical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Cowealth Medical Holding Co (ROCO:4745) is currently considered Fairly Valued. The stock's GF Value™ is NT$13.04, compared to a current price of NT$11.90 — trading 8.7% below its estimated fair value. The current Debt-to-EBITDA is -7.67. Cowealth Medical Holding Co's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cowealth Medical Holding Co (ROCO:4745), the current Debt-to-EBITDA is -7.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cowealth Medical Holding Co (ROCO:4745) Overvalued in 2026?
Based on GuruFocus' analysis, Cowealth Medical Holding Co stock appears to be undervalued.
The current stock price of NT$11.90 is trading 8.7% below its estimated GF Value™ of NT$13.04.
GuruFocus considers Cowealth Medical Holding Co to be Fairly Valued.
Key valuation signals for ROCO:4745:
Debt-to-EBITDA: -7.67
GF Value™: NT$13.04 vs. price of NT$11.90 (8.7% below fair value)
No single metric tells the full story. See the ROCO:4745 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cowealth Medical Holding Co Ltd is mainly involved in trading medical equipment, reagents, and spare parts. Its wide range of solutions includes refined management services tailored for in-vitro diagnostic products, reagents, and consumables, an integrated platform designed for decision-making and analysis, commercialization of achievements in medical science and technology, a Multi-Channel Coaxial Time Audio Video Imaging Platform (MCCTAVIP), and an AI-assisted system for clinical diagnosis. The Group has two reportable segments: Segment A, which generates maximum revenue and sells equipment, and Segment B, which sells reagents and others. Geographically, it generates maximum revenue from China and Hong Kong, and the rest from Taiwan.
55GF Score
Get the complete analysis for ROCO:4745
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4745 has been successfully added to your 
